Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Filings indexed 293 across all filing types
Latest filing 2022-11-17 Director's Dealing
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-11-17 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-17 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-17 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-17 English
FORM 4 SUBMISSION
Director's Dealing
2022-11-17 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a prospectus for an initial public offering (IPO) of common stock, detailing the offering size, price, underwriting, risk factors, business overview, management discussion, and financial statements. It is filed pursuant to Rule 424(b)(4), which is a prospectus filing related to securities offerings. The content focuses on the offering of shares, underwriting details, and company business description rather than financial results or regulatory certifications. This type of document is a capital markets offering document, specifically a prospectus for a stock issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs and share offerings.
2022-11-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.